Journal of Pharmaceutical Research International

SARS-CoV-2 has many biological traits, the pathogenic virus that caused the acute respiratory syndrome (SARS) epidemic in 2002. Clinical investigations have also discovered a link between CORONAVIRUS and cardiovascular illness. The coronavirus disease is caused by binding the viral spike protein to angiotensin-converting enzyme 2. It has spread around the world, affecting millions and millions of people. CORONAVIRUS looks to be connected to even worse results and an elevated risk of mortality in individuals before cardiovascular illness, even though CORONAVIRUS can cause myocardial damage, arrhythmia, acute coronary syndrome, and venous thromboembolism. Possible drug-disease interactions are becoming more concern for individuals with CORONAVIRUS and associated cardiac and vascular esses. By integrating our expertise of the virus's genetic makeups with clinical findings, we can better grasp the possible processes causing CO VID-19. This might pave the door for creating medicinal and pharmaceutical products. Pulmonary embolism is one of the most common acquired conditions in generalized hospitalized patients but an uncommon finding in patients with Covid. It has a penchant for thrombosis fueled by at least two separate yet interconnected processes i)A state of hypercoagulability and is Large vessel thrombosis and thromboembolism. ii)Direct vascular and endovascular damage. In situ microvascular thrombosis is caused by endothelial damage.PE can be presented in patients admitted to the ICU despite standard prophylactic anticoagulation. Deep vein thrombosis is present in significant cases of PE.